Neurobiology of Aging
Volume 32, Issue 8 , Pages 1379-1387 , August 2011

Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease

  • Andrea Marcello

      Affiliations

    • University Medicine of Goettingen, Department of Psychiatry, Goettingen, Germany
    • ,
  • Oliver Wirths

      Affiliations

    • University Medicine of Goettingen, Department of Psychiatry, Goettingen, Germany
    • ,
  • Thomas Schneider-Axmann

      Affiliations

    • University Medicine of Goettingen, Department of Psychiatry, Goettingen, Germany
    • ,
  • Malin Degerman-Gunnarsson

      Affiliations

    • Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Lars Lannfelt

      Affiliations

    • Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Thomas A. Bayer

      Affiliations

    • University Medicine of Goettingen, Department of Psychiatry, Goettingen, Germany
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry and Psychotherapy, Division of Molecular Psychiatry, University Medicine Goettingen, von-Siebold-Strasse 5, D-37075 Goettingen, Germany. Tel.: +49 0551 39 22912; fax: +49 0551 39 10291.

Received 11 May 2009 ,Revised 10 August 2009 ,Accepted 25 August 2009.

References 

  1. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 2001;58(3):373–379
  2. Association AP. Diagnostic and Statistical Manual of Mental Disorders–DSM-IV. 4 ed.. Washington, DC: American Psychiatric Association; 2000;
  3. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis. 2004;25(17):2912–2918
  4. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 1996;271(51):32916–32922
  5. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, Lemieux MC, Rufibach K, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2009;
  6. Cynis H, Schilling S, Bodnar M, Hoffmann T, Heiser U, Saido TC, et al. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta. 2006;1764(10):1618–1625
  7. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001;98(15):8850–8855
  8. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 2002;52(2):253–256
  9. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57(5):801–805
  10. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 2003;60(7):958–964
  11. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998;55(7):937–945
  12. Gaskin F, Finley J, Fang Q, Xu S, Fu SM. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J. Exp. Med. 1993;177(4):1181–1186
  13. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol. Aging. 2005;26(5):597–606
  14. Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci. Lett. 2007;427(3):127–131
  15. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007;64(3):354–362
  16. Gruden MA, Davudova TB, Malisauskas M, Zamotin VV, Sewell RD, Voskresenskaya NI, et al. Autoimmune responses to amyloid structures of Abeta(25–35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2004;18(2):165–171
  17. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, et al. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25–35)) oligomers, S100b and neurotransmitters. J. Neuroimmunol. 2007;186(1/2):181–192
  18. Guntert A, Dobeli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006;143(2):461–475
  19. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry. 2004;9(7):705–710
  20. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  21. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem. Biophys. Res. Commun. 2000;276(2):422–427
  22. He W, Barrow CJ. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry. 1999;38(33):10871–10877
  23. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38(4):547–554
  24. Hosoda R, Saido TC, Otvos L, Arai T, Mann DM, Lee VM, et al. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J. Neuropathol. Exp. Neurol. 1998;57(11):1089–1095
  25. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 2001;49(6):808–810
  26. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ. Full-length amyloid-beta (1–42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol. 1996;149(6):1823–1830
  27. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, et al. Cerebrospinal fluid Abeta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 1999;45(4):504–511
  28. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 1998;44(1):17–26
  29. Katarzyna AG, Matthew RG, Hyoung-gon L, Rudy JC, Michael GZ, Annamalai P, et al. Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J. Neurochem. 2008;106(3):1350–1356
  30. Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr. Opin. Psychiatry. 2008;21(3):260–267
  31. Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J. Neural. Transm. 2008;115(12):1651–1659
  32. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology. 1997;48(3):741–745
  33. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun. 1997;237(1):188–191
  34. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta. 1998;1406(3):291–298
  35. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun. 2000;268(3):750–756
  36. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001;276(16):12991–12998
  37. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging. 2004;25(3):273–281
  38. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease. J. Neural Transm. 2009;
  39. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, et al. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann. Neurol. 1999;45(4):537–541
  40. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood–brain barrier in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007;23(4):241–245
  41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  42. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch. Neurol. 2000;57(1):100–105
  43. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 2001;304(1/2):102–106
  44. Miller DL, Potempska A, Mehta PD. Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence. Amyloid. 2007;14(1):39–50
  45. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry. 2005;44(32):10810–10821
  46. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem. 1992;267(24):17082–17086
  47. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003;3(1):29–39
  48. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging. 2006;27(6):904–905
  49. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, et al. {beta}-Amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem. 2005;280(40):34186–34192
  50. Piccini A, Zanusso G, Borghi R, Noviello C, Monaco S, Russo R, et al. Association of a Presenilin 1 S170F mutation with a Novel Alzheimer Disease molecular phenotype. Arch. Neurol. 2007;64(5):738–745
  51. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995;270(41):23895–23898
  52. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1–42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am. J. Geriatr. Psychiatry. 2005;13(10):914–917
  53. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett. 1997;409(3):411–416
  54. Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, et al. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiol. Dis. 2001;8(1):173–180
  55. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, et al. Pyroglutamate-modified amyloid -peptides – AbetaN3(pE) – strongly affect cultured neuron and astrocyte survival. J. Neurochem. 2002;82(6):1480–1489
  56. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques. Neuron. 1995;14(2):457–466
  57. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 1996;215(3):173–176
  58. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004;563(1–3):191–196
  59. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry. 2006;45(41):12393–12399
  60. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 2008;14(10):1106–1111
  61. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch. Neurol. 2008;65(2):256–263
  62. Suzuki N, Cheung TT, Cai X-D, Odaka A, Otvos LJ, Eckmann C, et al. An increased percentage of long amyloid ß protein is secreated by familial amyloid ß protein precursor (ßAPP717) mutants. Science. 1994;264:1336–1340
  63. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 1996;141(1/2):65–68
  64. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol. Aging. 2000;21(5):735–740
  65. Tekirian TL, Saido TC, Markesbery WR, Russell MJ, Wekstein DR, Patel E, et al. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol. 1998;57(1):76–94
  66. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging. 1996;17(4):541–547
  67. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1–40) and Abeta(1–42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655–660
  68. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid. 2000;7(4):245–258
  69. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002;37(7):943–948
  70. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004;256(3):240–246
  71. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth H-U, Ta B. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009;118(4):487–496
  72. Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein–Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 1997;94(1–3):213–222
  73. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, et al. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res. 2008;1219:169–179

PII: S0197-4580(09)00290-5

doi: 10.1016/j.neurobiolaging.2009.08.011

Neurobiology of Aging
Volume 32, Issue 8 , Pages 1379-1387 , August 2011

Article Tools

* Image Usage & Resolution